GlaxoSmithKline Pharmaceuticals Limited
GLAXO · 500660 · Healthcare · Pharmaceuticals
- Market cap
- Rs 42,608 Cr
- P/E
- 40.56x
- P/B
- 18.79x
- 52W high / low
- Rs 3,120.7 / Rs 2,088.1
About GlaxoSmithKline Pharmaceuticals
GlaxoSmithKline Pharmaceuticals Limited is listed on the NSE under the symbol GLAXO and on the BSE under scrip code 500660. It is classified in the Healthcare sector, industry: Pharmaceuticals. It is a constituent of BSE 200, NIFTY 500 and NIFTY Midcap 150. The company listed on 15 Dec 2000 and has a face value of Rs 10.
The latest available end-of-day price is Rs 2,515.1 (+0.68% on the day), for a market capitalisation of Rs 42,608 Cr. Trailing P/E is 40.56x and price-to-book is 18.79x. The 52-week range is Rs 2,088.1 to Rs 3,120.7. The latest price is 41% of the way from the 52-week low to the 52-week high.
Against the 16-company comparison set from the official BSE basic industry Pharmaceuticals, its market capitalisation is 0.4 times the peer median of Rs 1,05,844 Cr, and its P/E of 40.56x compares with a peer median of 37.86x. The comparison set is chosen mechanically from the exchange classification; it is not a ranking.
Latest annual results
For FY26 (year ended 31 Mar 2026), GlaxoSmithKline Pharmaceuticals Limited reported revenue of Rs 3,822 Cr and net profit of Rs 1,036 Cr, with a net margin of 27.11% and earnings per share of Rs 54.52 (consolidated statements).
Year-on-year change: revenue +1.85%; net profit +11.69%; EPS 0.00%. Three-year compound annual growth rate: revenue +5.77%; net profit +19.26%.
At the same date the balance sheet shows total assets of Rs 4,324 Cr, shareholders' equity of Rs 2,267 Cr, total debt of Rs 0 Cr, cash of Rs 1,102 Cr, a debt-to-equity ratio of 0.00 and operating cash flow of Rs 903 Cr.
On a trailing-twelve-month basis the filings add up to revenue of Rs 3,955 Cr, net income of Rs 1,068 Cr and a net margin of 27.01%.
Shareholding pattern
In the shareholding pattern for 30 Sept 2026, GlaxoSmithKline Pharmaceuticals Limited's ownership is split: promoters 75.00%; foreign institutional investors (FIIs) 4.75%; domestic institutional investors (DIIs) 8.48%; retail and other shareholders 11.77%.
Compared with the filing for 30 Jun 2026: promoter holding 0.00 percentage points; FII holding −0.04 percentage points; DII holding +0.68 percentage points.
The same filing lists reported promoter pledge of 0.00% and 1,19,337 shareholders on record.
Figures are raw disclosures from official NSE/BSE and SEBI filings plus mechanically computed ratios, restated in words. This is research data, not investment advice, a rating or a recommendation; DalalOS is not a SEBI-registered investment advisor.
More
Peer comparison
Official BSE basic industry: Pharmaceuticals. Limited to companies within a 0.1x–10x market-cap band.
Edit columns
| Sun Pharmaceutical Industries Limited | Rs 1,761 | Rs 4,22,517 Cr | Rs 62,141 Cr | Rs 12,117 Cr | 34.94x | 15.53% |
| Divi's Laboratories Limited | Rs 9,664 | Rs 2,56,096 Cr | Rs 11,682 Cr | Rs 2,925 Cr | 87.69x | 18.44% |
| Torrent Pharmaceuticals Limited | Rs 4,580 | Rs 1,55,015 Cr | Rs 15,654 Cr | Rs 2,156 Cr | 73.16x | 27.30% |
| Laurus Labs Limited | Rs 2,244 | Rs 1,21,232 Cr | Rs 7,323 Cr | Rs 1,091 Cr | — | 22.38% |
| Zydus Lifesciences Limited | Rs 1,184.4 | Rs 1,18,203 Cr | Rs 29,052 Cr | Rs 4,593 Cr | 26.40x | 17.68% |
| Dr. Reddy's Laboratories Limited | Rs 1,345 | Rs 1,12,308 Cr | Rs 34,353 Cr | Rs 2,760 Cr | 40.02x | 7.84% |
| Cipla Limited | Rs 1,358 | Rs 1,09,706 Cr | Rs 28,855 Cr | Rs 2,854 Cr | 37.86x | 8.83% |
| Mankind Pharma Limited | Rs 2,469.3 | Rs 1,01,982 Cr | Rs 15,705 Cr | Rs 2,264 Cr | 45.45x | 14.78% |
| Aurobindo Pharma Limited | Rs 1,659.9 | Rs 95,511 Cr | Rs 35,625 Cr | Rs 3,711 Cr | 25.94x | 10.53% |
| Lupin Limited | Rs 1,989.9 | Rs 90,988 Cr | Rs 30,442 Cr | Rs 5,551 Cr | 16.44x | 27.89% |
| Glenmark Pharmaceuticals Limited | Rs 2,339 | Rs 66,007 Cr | Rs 18,236 Cr | Rs 1,798 Cr | 36.71x | 15.46% |
| Alkem Laboratories Limited | Rs 5,079 | Rs 60,719 Cr | Rs 15,681 Cr | Rs 2,204 Cr | 28.15x | 16.72% |
| Biocon Limited | Rs 351.9 | Rs 57,346 Cr | Rs 17,638 Cr | Rs 416 Cr | — | 1.78% |
| Abbott India Limited | Rs 26,145 | Rs 55,558 Cr | Rs 7,295 Cr | Rs 1,615 Cr | 34.41x | 35.85% |
| Gland Pharma Limited | Rs 3,074.5 | Rs 50,717 Cr | Rs 7,045 Cr | Rs 1,129 Cr | 44.88x | 11.57% |
| GlaxoSmithKline Pharmaceuticals LimitedThis company | Rs 2,515.1 | Rs 42,608 Cr | Rs 4,100 Cr | Rs 1,068 Cr | 40.56x | 50.64% |
| Median | Rs 2,356.65 | Rs 1,05,844 Cr | Rs 15,693 Cr | Rs 2,512 Cr | 37.86x | 17.20% |
Peers are selected mechanically from the official BSE industry hierarchy and current market-cap band. This is a comparison set, not a ranking or recommendation.
Companies related to GlaxoSmithKline Pharmaceuticals
Same official industry (Pharmaceuticals)
- Sun Pharmaceutical Industries LimitedSUNPHARMA · Market cap Rs 4,22,517 Cr
- Divi's Laboratories LimitedDIVISLAB · Market cap Rs 2,56,096 Cr
- Torrent Pharmaceuticals LimitedTORNTPHARM · Market cap Rs 1,55,015 Cr
- Laurus Labs LimitedLAURUSLABS · Market cap Rs 1,21,232 Cr
- Zydus Lifesciences LimitedZYDUSLIFE · Market cap Rs 1,18,203 Cr
- Dr. Reddy's Laboratories LimitedDRREDDY · Market cap Rs 1,12,308 Cr
- Cipla LimitedCIPLA · Market cap Rs 1,09,706 Cr
- Mankind Pharma LimitedMANKIND · Market cap Rs 1,01,982 Cr
Other Healthcare companies of a similar market capitalisation
- Gland Pharma LimitedGLAND · Market cap Rs 50,717 Cr
- IPCA Laboratories LimitedIPCALAB · Market cap Rs 48,868 Cr
- Anthem Biosciences LimitedANTHEM · Market cap Rs 46,769 Cr
- Ajanta Pharma LimitedAJANTPHARM · Market cap Rs 43,367 Cr
- Emcure Pharmaceuticals LimitedEMCURE · Market cap Rs 35,376 Cr
- Aster DM Quality Care LimitedASTERDM · Market cap Rs 35,191 Cr
- Narayana Hrudayalaya Ltd.NH · Market cap Rs 35,038 Cr
- Global Health LimitedMEDANTA · Market cap Rs 34,932 Cr
Companies are grouped mechanically from the exchange classification and listed by market capitalisation. This is a comparison set, not a ranking or recommendation.